novo nordisk - Search News

Novo Nordisk, Eli Lilly and Trump

Eli Lilly, Novo Nordisk negotiating deal with Trump admin on obesity drug prices

The Trump administration is negotiating an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their weight loss drugs at a lower price through TrumpRx, sources familiar with the talks told ABC News.

· 11h

Lilly and Novo Nordisk Near White House Deal on Obesity Drug Prices, Endpoints News Reports

STAT · 5h

Trump administration nears deals for cheaper weight loss drugs with Novo Nordisk, Eli Lilly

Novo Nordisk, Pfizer sweeten bid for Metsera

Digest more

· 5h · on MSN

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

· 10h · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

· 21h

Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit

· 13h

Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies

Last week, Novo came over the top of an original Pfizer deal with Metsera with an up to $9bn offer for the biotech, sparking one of the most contentious bidding wars over a biotech in recent memory.

· 21h

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

· 15h

Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S.

14h

Novo Nordisk AS (OCSE:NOVO B) Q3 2025: Everything You Need To Know Ahead Of Earnings

This article first appeared on GuruFocus. Novo Nordisk AS (OCSE:NOVO B) is set to release its Q3 2025 earnings on Nov 5, 2025. The consensus estimate for Q3 2025 revenue is $77.50 billion, and the earnings are expected to come in at $5.

11h

Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster blood thinner helped it post third-quarter earnings above expectations.

Novethic

Pfizer contre Novo Nordisk : la bataille des milliards autour des médicaments coupe-faim

Pfizer et Novo Nordisk se livrent une guerre de milliards pour se positionner sur le marché florissant des médicaments coupe-faim.

Novo Nordisk, Eli Lilly and Trump

Novo Nordisk, Pfizer sweeten bid for Metsera

Novo Nordisk AS (OCSE:NOVO B) Q3 2025: Everything You Need To Know Ahead Of Earnings

Pfizer, Novo Nordisk escalate bidding war for obesity drug developer Metsera

Pfizer contre Novo Nordisk : la bataille des milliards autour des médicaments coupe-faim

Related topics